Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia

被引：4

作者：

Baird, R

van Zyl-Smit, RN

Iveson, A

Duddy, J

Rassam, S

机构：

[1] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

[2] Queen Marys Sidcup NHS Trust, Dept Haematol & Oncol, Sidcup DA14 6LT, Kent, England

[3] Chelsfield Pk Hosp, Orpington BR5 6RG, Kent, England

来源：

LEUKEMIA & LYMPHOMA | 2004年 / 45卷 / 01期

关键词：

acute myeloid leukaemia (AML); meningeal; myelodysplasia; non-Hodgkin's lymphoma (NHL); thalidomide;

D O I：

10.1080/1042819031000149412

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non-Hodgkin's lymphoma (NHL) who developed meningeal leukaemia. This was refractory to systemic and intrathecal chemotherapy and cranial irradiation. Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB). We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course. The patient, however, progressed systemically and succumbed to her illness.

引用

页码：179 / 181

页数：3

共 14 条

[1]

INCIDENCE AND CHARACTERIZATION OF SECONDARY MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA FOLLOWING HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR LYMPHOID MALIGNANCIES [J].